speb/financial-data huggingface dataset:
PHARM.AS cash_flow (annual, 2021-12-31) — Purchase Of Business: 0.00
PHARM.AS income_statement (annual, 2021-12-31) — Restructuring And Mergern Acquisition: 0.00
PHARM.AS cash_flow (annual, 2021-12-31) — Sale Of Business: 0.00
PHARM.AS income_statement (annual, 2022-12-31) — +Operating Expense: 178200000.00
PHARM.AS income_statement (annual, 2022-12-31) — +Total Revenue: 205622000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Accounts Payable: 8753000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Accounts Receivable: 20964000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -19989000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 462297000.00
PHARM.AS income_statement (annual, 2022-12-31) — Amortization: 4257000.00
PHARM.AS income_statement (annual, 2022-12-31) — Amortization Of Intangibles Income Statement: 4257000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Available For Sale Securities: 403000.00
PHARM.AS income_statement (annual, 2022-12-31) — Basic Average Shares: 651142857.00
PHARM.AS income_statement (annual, 2022-12-31) — Basic EPS: 0.02
PHARM.AS cash_flow (annual, 2022-12-31) — Beginning Cash Position: 191924000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Buildings And Improvements: 32884000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Capital Expenditure: -1977000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Capital Expenditure Reported: -1376000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 33308000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Capital Stock: 7509000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 207342000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 207342000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Cash Dividends Paid: 0.00
PHARM.AS cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: -4982000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: 5323000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: 22458000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Change In Inventory: -15016000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Change In Other Working Capital: 273000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Change In Payable: 11992000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: 11992000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Change In Receivables: 2364000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Change In Working Capital: -387000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Changes In Cash: 22799000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Common Stock: 7509000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Common Stock Equity: 204638000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Common Stock Issuance: 2281000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Construction In Progress: 6000.00
PHARM.AS income_statement (annual, 2022-12-31) — Cost Of Revenue: 17562000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Current Accrued Expenses: 43613000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Current Assets: 277500000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Current Capital Lease Obligation: 3465000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Current Debt: 1768000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 5233000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Current Liabilities: 59698000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Depreciation: 13188000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 13188000.00
PHARM.AS income_statement (annual, 2022-12-31) — Depreciation Amortization Depletion Income Statement: 7154000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 13188000.00
PHARM.AS income_statement (annual, 2022-12-31) — Depreciation And Amortization In Income Statement: 7154000.00
PHARM.AS income_statement (annual, 2022-12-31) — Depreciation Income Statement: 2897000.00
PHARM.AS income_statement (annual, 2022-12-31) — Diluted Average Shares: 719684211.00
PHARM.AS income_statement (annual, 2022-12-31) — Diluted EPS: 0.02
PHARM.AS income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: 13674000.00
PHARM.AS income_statement (annual, 2022-12-31) — EBIT: 20345000.00
PHARM.AS income_statement (annual, 2022-12-31) — EBITDA: 33533000.00
PHARM.AS income_statement (annual, 2022-12-31) — Earnings From Equity Interest: -1083000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Earnings Losses From Equity Investments: 1083000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: -7381000.00
PHARM.AS cash_flow (annual, 2022-12-31) — End Cash Position: 207342000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 6827000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Financing Cash Flow: -4982000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Finished Goods: 12460000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Free Cash Flow: 20481000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Gain Loss On Investment Securities: 1185000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of Business: -12242000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of PPE: 0.00
PHARM.AS income_statement (annual, 2022-12-31) — Gain On Sale Of Business: 12242000.00
PHARM.AS income_statement (annual, 2022-12-31) — Gain On Sale Of Ppe: 0.00
PHARM.AS income_statement (annual, 2022-12-31) — Gain On Sale Of Security: 3215000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: -8737000.00
PHARM.AS income_statement (annual, 2022-12-31) — General And Administrative Expense: 62443000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 75121000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Gross PPE: 59134000.00
PHARM.AS income_statement (annual, 2022-12-31) — Gross Profit: 188060000.00
PHARM.AS income_statement (annual, 2022-12-31) — Impairment Of Capital Assets: 4376000.00
PHARM.AS income_statement (annual, 2022-12-31) — Interest Expense: 5358000.00
PHARM.AS income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 5358000.00
PHARM.AS income_statement (annual, 2022-12-31) — Interest Income: 85000.00
PHARM.AS income_statement (annual, 2022-12-31) — Interest Income Non Operating: 85000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Interest Paid Cff: -3952000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Interest Received Cfo: 85000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Inventory: 42326000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Invested Capital: 338024000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Investing Cash Flow: 5323000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Investmentin Financial Assets: 7230000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Investments And Advances: 9731000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Investments In Other Ventures Under Equity Method: 2501000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 2281000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Issuance Of Debt: 0.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Land And Improvements: 0.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Leases: 5282000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 29843000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Long Term Debt: 131618000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 161461000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Long Term Debt Issuance: 0.00
PHARM.AS cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -3311000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Long Term Equity Investment: 2501000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 16271000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Net Business Purchase And Sale: 7300000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 2281000.00
PHARM.AS income_statement (annual, 2022-12-31) — Net Income: 13674000.00
PHARM.AS income_statement (annual, 2022-12-31) — Net Income Common Stockholders: 13674000.00
PHARM.AS income_statement (annual, 2022-12-31) — Net Income Continuous Operations: 13674000.00
PHARM.AS income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: 13674000.00
PHARM.AS income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: 13674000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: 14987000.00
PHARM.AS income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: 13674000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Net Intangibles Purchase And Sale: -601000.00
PHARM.AS income_statement (annual, 2022-12-31) — Net Interest Income: -5378000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Net Investment Purchase And Sale: 0.00
PHARM.AS cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: -3311000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -3311000.00
PHARM.AS income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: -5378000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Net PPE: 39145000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 129517000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Non Current Deferred Assets: 22973000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Assets: 22973000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Non Current Prepaid Assets: 228000.00
PHARM.AS income_statement (annual, 2022-12-31) — Normalized EBITDA: 22452000.00
PHARM.AS income_statement (annual, 2022-12-31) — Normalized Income: 3563798.23
PHARM.AS cash_flow (annual, 2022-12-31) — Operating Cash Flow: 22458000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Operating Gains Losses: -11159000.00
PHARM.AS income_statement (annual, 2022-12-31) — Operating Income: 9860000.00
PHARM.AS income_statement (annual, 2022-12-31) — Operating Revenue: 205622000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 656348225.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Other Current Borrowings: 1768000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Other Equity Adjustments: -8737000.00
PHARM.AS income_statement (annual, 2022-12-31) — Other Gand A: 14717000.00
PHARM.AS income_statement (annual, 2022-12-31) — Other Income Expense: 10505000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 75121000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Other Non Cash Items: 587000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Other Non Current Assets: 1099000.00
PHARM.AS income_statement (annual, 2022-12-31) — Other Non Operating Income Expenses: 507000.00
PHARM.AS income_statement (annual, 2022-12-31) — Other Operating Expenses: 49662000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Other Properties: 4691000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Other Receivables: 1117000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Other Short Term Investments: 0.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Payables: 10852000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 54465000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Prepaid Assets: 2288000.00
PHARM.AS income_statement (annual, 2022-12-31) — Pretax Income: 14987000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Proceeds From Stock Option Exercised: 2281000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Properties: 0.00
PHARM.AS cash_flow (annual, 2022-12-31) — Purchase Of Intangibles: -601000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Purchase Of Investment: 0.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Raw Materials: 313000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Receivables: 25331000.00
PHARM.AS income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 11528000.00
PHARM.AS income_statement (annual, 2022-12-31) — Reconciled Depreciation: 13188000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Repayment Of Debt: -3311000.00
PHARM.AS income_statement (annual, 2022-12-31) — Research And Development: 52531000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Restricted Cash: 213000.00
PHARM.AS income_statement (annual, 2022-12-31) — Restructuring And Mergern Acquisition: 0.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Retained Earnings: -256431000.00
PHARM.AS income_statement (annual, 2022-12-31) — Salaries And Wages: 47726000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Sale Of Business: 7300000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Sale Of Investment: 0.00
PHARM.AS income_statement (annual, 2022-12-31) — Selling And Marketing Expense: 6410000.00
PHARM.AS income_statement (annual, 2022-12-31) — Selling General And Administration: 68853000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Share Issued: 656348225.00
PHARM.AS income_statement (annual, 2022-12-31) — Special Income Charges: 7866000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Stock Based Compensation: 6392000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Stockholders Equity: 204638000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Tangible Book Value: 129517000.00
PHARM.AS income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 970798.23
PHARM.AS income_statement (annual, 2022-12-31) — Tax Provision: 1313000.00
PHARM.AS income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.09
PHARM.AS balance_sheet (annual, 2022-12-31) — Taxes Receivable: 3250000.00
PHARM.AS cash_flow (annual, 2022-12-31) — Taxes Refund Paid: -1235000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Total Assets: 425797000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Total Capitalization: 336256000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Total Debt: 166694000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 204638000.00
PHARM.AS income_statement (annual, 2022-12-31) — Total Expenses: 195762000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 221159000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 148297000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 161461000.00
PHARM.AS income_statement (annual, 2022-12-31) — Total Operating Income As Reported: 18233000.00
PHARM.AS income_statement (annual, 2022-12-31) — Total Other Finance Cost: 105000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Total Tax Payable: 2099000.00
PHARM.AS income_statement (annual, 2022-12-31) — Total Unusual Items: 11081000.00
PHARM.AS income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: 11081000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Work In Process: 29553000.00
PHARM.AS balance_sheet (annual, 2022-12-31) — Working Capital: 217802000.00
PHARM.AS income_statement (annual, 2023-12-31) — +Operating Expense: 242393000.00
PHARM.AS income_statement (annual, 2023-12-31) — +Total Revenue: 245316000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Accounts Payable: 16022000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Accounts Receivable: 35408000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -26931000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 478431000.00
PHARM.AS income_statement (annual, 2023-12-31) — Amortization: 5635000.00
PHARM.AS income_statement (annual, 2023-12-31) — Amortization Of Intangibles Income Statement: 5635000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Available For Sale Securities: 2020000.00
PHARM.AS income_statement (annual, 2023-12-31) — Basic Average Shares: 674600000.00
PHARM.AS income_statement (annual, 2023-12-31) — Basic EPS: -0.02
PHARM.AS cash_flow (annual, 2023-12-31) — Beginning Cash Position: 207342000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Buildings And Improvements: 30959000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Capital Expenditure: -1464000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Capital Expenditure Reported: -1437000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 33123000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Capital Stock: 7669000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 61741000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 213424000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Cash Dividends Paid: 0.00
PHARM.AS cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Financing Activities: -1039000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Investing Activities: -129388000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: -17302000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Change In Inventory: -14434000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Change In Other Working Capital: -216000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Change In Payable: 16228000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: 16228000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Change In Receivables: -18539000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Change In Working Capital: -16961000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Changes In Cash: -147729000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Common Stock: 7669000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Common Stock Equity: 218781000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Construction In Progress: 179000.00
PHARM.AS income_statement (annual, 2023-12-31) — Cost Of Revenue: 25212000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Current Accrued Expenses: 50272000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Current Assets: 316342000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 3616000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Current Debt: 1824000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 5440000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Current Liabilities: 77968000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Depreciation: 15925000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 15925000.00
PHARM.AS income_statement (annual, 2023-12-31) — Depreciation Amortization Depletion Income Statement: 9156000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 15925000.00
PHARM.AS income_statement (annual, 2023-12-31) — Depreciation And Amortization In Income Statement: 9156000.00
PHARM.AS income_statement (annual, 2023-12-31) — Depreciation Income Statement: 3521000.00
PHARM.AS income_statement (annual, 2023-12-31) — Diluted Average Shares: 674600000.00
PHARM.AS income_statement (annual, 2023-12-31) — Diluted EPS: -0.02
PHARM.AS income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -10548000.00
PHARM.AS income_statement (annual, 2023-12-31) — EBIT: -6048000.00
PHARM.AS income_statement (annual, 2023-12-31) — EBITDA: 9877000.00
PHARM.AS income_statement (annual, 2023-12-31) — Earnings From Equity Interest: -289000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Earnings Losses From Equity Investments: 289000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: 2128000.00
PHARM.AS cash_flow (annual, 2023-12-31) — End Cash Position: 61741000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 6093000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Financing Cash Flow: -1039000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Finished Goods: 18349000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Free Cash Flow: -18766000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Gain Loss On Investment Securities: 930000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of Business: 0.00
PHARM.AS cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of PPE: 0.00
PHARM.AS income_statement (annual, 2023-12-31) — Gain On Sale Of Business: 0.00
PHARM.AS income_statement (annual, 2023-12-31) — Gain On Sale Of Ppe: 21279000.00
PHARM.AS income_statement (annual, 2023-12-31) — Gain On Sale Of Security: -3901000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: -2057000.00
PHARM.AS income_statement (annual, 2023-12-31) — General And Administrative Expense: 80684000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 71267000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Gross PPE: 60397000.00
PHARM.AS income_statement (annual, 2023-12-31) — Gross Profit: 220104000.00
PHARM.AS income_statement (annual, 2023-12-31) — Impairment Of Capital Assets: 4663000.00
PHARM.AS income_statement (annual, 2023-12-31) — Interest Expense: 5964000.00
PHARM.AS income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 5964000.00
PHARM.AS income_statement (annual, 2023-12-31) — Interest Income: 3663000.00
PHARM.AS income_statement (annual, 2023-12-31) — Interest Income Non Operating: 3663000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Interest Paid Cff: -5134000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Interest Received Cfo: 2883000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Inventory: 56760000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Invested Capital: 357203000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Investing Cash Flow: -129388000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Investmentin Financial Assets: 8113000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Investments And Advances: 10398000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Investmentsin Associatesat Cost: 2285000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Issuance Of Debt: 0.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Land And Improvements: 0.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Leases: 5546000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 29507000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Long Term Debt: 136598000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 166105000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Long Term Debt Issuance: 0.00
PHARM.AS cash_flow (annual, 2023-12-31) — Long Term Debt Payments: -4038000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Long Term Equity Investment: 2285000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 18582000.00
PHARM.AS income_statement (annual, 2023-12-31) — Minority Interests: 0.00
PHARM.AS cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: 0.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Net Debt: 76681000.00
PHARM.AS income_statement (annual, 2023-12-31) — Net Income: -10548000.00
PHARM.AS income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -10548000.00
PHARM.AS income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -10548000.00
PHARM.AS income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -10548000.00
PHARM.AS income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -10548000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -12012000.00
PHARM.AS income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -10548000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Net Intangibles Purchase And Sale: -27000.00
PHARM.AS income_statement (annual, 2023-12-31) — Net Interest Income: -2435000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: -149203000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: -4038000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: -4038000.00
PHARM.AS income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: -2435000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Net Other Investing Changes: 21279000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Net PPE: 33466000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 147514000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Non Current Deferred Assets: 29761000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Assets: 29761000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Non Current Prepaid Assets: 92000.00
PHARM.AS income_statement (annual, 2023-12-31) — Normalized EBITDA: -2838000.00
PHARM.AS income_statement (annual, 2023-12-31) — Normalized Income: -21713319.68
PHARM.AS cash_flow (annual, 2023-12-31) — Operating Cash Flow: -17302000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Operating Gains Losses: -20990000.00
PHARM.AS income_statement (annual, 2023-12-31) — Operating Income: -22289000.00
PHARM.AS income_statement (annual, 2023-12-31) — Operating Revenue: 245316000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 671073243.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Other Current Borrowings: 1824000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Other Equity Adjustments: -2057000.00
PHARM.AS income_statement (annual, 2023-12-31) — Other Gand A: 14990000.00
PHARM.AS income_statement (annual, 2023-12-31) — Other Income Expense: 12712000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Other Intangible Assets: 71267000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Other Non Cash Items: 5257000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Other Non Current Assets: 1528000.00
PHARM.AS income_statement (annual, 2023-12-31) — Other Non Operating Income Expenses: 286000.00
PHARM.AS income_statement (annual, 2023-12-31) — Other Operating Expenses: 76822000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Other Properties: 5131000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Other Receivables: 2145000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Other Short Term Investments: 151683000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Payables: 22256000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 72528000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Prepaid Assets: 3543000.00
PHARM.AS income_statement (annual, 2023-12-31) — Pretax Income: -12012000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: 8133000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Properties: 0.00
PHARM.AS cash_flow (annual, 2023-12-31) — Purchase Of Business: 0.00
PHARM.AS cash_flow (annual, 2023-12-31) — Purchase Of Intangibles: -27000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Purchase Of Investment: -382014000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Raw Materials: 705000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Receivables: 42615000.00
PHARM.AS income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 18443000.00
PHARM.AS income_statement (annual, 2023-12-31) — Reconciled Depreciation: 15925000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Repayment Of Debt: -4038000.00
PHARM.AS income_statement (annual, 2023-12-31) — Research And Development: 68914000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Restricted Cash: 0.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Retained Earnings: -265262000.00
PHARM.AS income_statement (annual, 2023-12-31) — Salaries And Wages: 65694000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Sale Of Business: 0.00
PHARM.AS cash_flow (annual, 2023-12-31) — Sale Of Investment: 232811000.00
PHARM.AS income_statement (annual, 2023-12-31) — Selling And Marketing Expense: 6817000.00
PHARM.AS income_statement (annual, 2023-12-31) — Selling General And Administration: 87501000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Share Issued: 671073243.00
PHARM.AS income_statement (annual, 2023-12-31) — Special Income Charges: 16616000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Stock Based Compensation: 9251000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Stockholders Equity: 218781000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Tangible Book Value: 147514000.00
PHARM.AS income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: 1549680.32
PHARM.AS income_statement (annual, 2023-12-31) — Tax Provision: -1464000.00
PHARM.AS income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.12
PHARM.AS balance_sheet (annual, 2023-12-31) — Taxes Receivable: 5062000.00
PHARM.AS cash_flow (annual, 2023-12-31) — Taxes Refund Paid: -655000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Total Assets: 462854000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Total Capitalization: 355379000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Total Debt: 171545000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 218781000.00
PHARM.AS income_statement (annual, 2023-12-31) — Total Expenses: 267605000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 244073000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 146512000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 166105000.00
PHARM.AS income_statement (annual, 2023-12-31) — Total Operating Income As Reported: -5387000.00
PHARM.AS income_statement (annual, 2023-12-31) — Total Other Finance Cost: 134000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Total Tax Payable: 6234000.00
PHARM.AS income_statement (annual, 2023-12-31) — Total Unusual Items: 12715000.00
PHARM.AS income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: 12715000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Work In Process: 37706000.00
PHARM.AS balance_sheet (annual, 2023-12-31) — Working Capital: 238374000.00
PHARM.AS income_statement (quarterly, 2024-09-30) — Basic Average Shares: 517000000.00
PHARM.AS income_statement (quarterly, 2024-09-30) — Basic EPS: 0.00
PHARM.AS income_statement (quarterly, 2024-09-30) — Diluted Average Shares: 517000000.00
PHARM.AS income_statement (quarterly, 2024-09-30) — Diluted EPS: 0.00
PHARM.AS income_statement (quarterly, 2024-09-30) — Gain On Sale Of Security: 21000.00
PHARM.AS balance_sheet (quarterly, 2024-09-30) — Net Debt: 34756000.00
PHARM.AS income_statement (quarterly, 2024-09-30) — Other Operating Expenses: -777000.00
PHARM.AS cash_flow (quarterly, 2024-09-30) — Sale Of Intangibles: 0.00
PHARM.AS income_statement (quarterly, 2024-09-30) — Total Unusual Items: 21000.00
PHARM.AS income_statement (quarterly, 2024-09-30) — Total Unusual Items Excluding Goodwill: 21000.00
PHARM.AS income_statement (annual, 2024-12-31) — +Operating Expense: 265466000.00
PHARM.AS income_statement (annual, 2024-12-31) — +Total Revenue: 297200000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Accounts Payable: 10103000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Accounts Receivable: 41531000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -29949000.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -29949000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 488990000.00
PHARM.AS income_statement (annual, 2024-12-31) — Amortization: 6041000.00
PHARM.AS income_statement (annual, 2024-12-31) — Amortization Of Intangibles Income Statement: 6041000.00
PHARM.AS income_statement (annual, 2024-12-31) — Basic Average Shares: 687750000.00
PHARM.AS income_statement (quarterly, 2024-12-31) — Basic Average Shares: 725000000.00
PHARM.AS income_statement (annual, 2024-12-31) — Basic EPS: -0.02
PHARM.AS income_statement (quarterly, 2024-12-31) — Basic EPS: 0.00
PHARM.AS cash_flow (annual, 2024-12-31) — Beginning Cash Position: 61741000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Buildings And Improvements: 24534000.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Buildings And Improvements: 24534000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Capital Expenditure: -796000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Capital Expenditure Reported: -790000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 29914000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Capital Stock: 7769000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 54944000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 167893000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Cash Dividends Paid: 0.00
PHARM.AS cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: -34412000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: 31618000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: -1795000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Change In Inventory: -503000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Change In Other Working Capital: -17000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Change In Payable: -2769000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: -2769000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Change In Receivables: -6783000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Change In Working Capital: -10072000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Changes In Cash: -4589000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Common Stock: 7769000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Common Stock Equity: 221061000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Construction In Progress: 145000.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Construction In Progress: 145000.00
PHARM.AS income_statement (annual, 2024-12-31) — Cost Of Revenue: 35399000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 53224000.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Current Accrued Expenses: 53224000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Current Assets: 278440000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 2946000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Current Debt: 4245000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 7191000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Current Liabilities: 73802000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Depreciation: 16070000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 16070000.00
PHARM.AS income_statement (annual, 2024-12-31) — Depreciation Amortization Depletion Income Statement: 9361000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 16070000.00
PHARM.AS income_statement (annual, 2024-12-31) — Depreciation And Amortization In Income Statement: 9361000.00
PHARM.AS income_statement (annual, 2024-12-31) — Depreciation Income Statement: 3320000.00
PHARM.AS income_statement (annual, 2024-12-31) — Diluted Average Shares: 687750000.00
PHARM.AS income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 725000000.00
PHARM.AS income_statement (annual, 2024-12-31) — Diluted EPS: -0.02
PHARM.AS income_statement (quarterly, 2024-12-31) — Diluted EPS: 0.00
PHARM.AS income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -11841000.00
PHARM.AS income_statement (annual, 2024-12-31) — EBIT: 245000.00
PHARM.AS income_statement (annual, 2024-12-31) — EBITDA: 16315000.00
PHARM.AS income_statement (annual, 2024-12-31) — Earnings From Equity Interest: -1760000.00
PHARM.AS income_statement (quarterly, 2024-12-31) — Earnings From Equity Interest: -484000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Earnings Losses From Equity Investments: 1758000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: -2208000.00
PHARM.AS cash_flow (annual, 2024-12-31) — End Cash Position: 54944000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 3767000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Financing Cash Flow: -34412000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Finished Goods: 16297000.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Finished Goods: 16297000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Free Cash Flow: -2591000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Gain Loss On Investment Securities: -4990000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of Business: 0.00
PHARM.AS cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of PPE: 22000.00
PHARM.AS income_statement (annual, 2024-12-31) — Gain On Sale Of Business: 0.00
PHARM.AS income_statement (annual, 2024-12-31) — Gain On Sale Of Ppe: 0.00
PHARM.AS income_statement (annual, 2024-12-31) — Gain On Sale Of Security: 6975000.00
PHARM.AS income_statement (quarterly, 2024-12-31) — Gain On Sale Of Security: 1816000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: -209000.00
PHARM.AS income_statement (annual, 2024-12-31) — General And Administrative Expense: 92081000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Goodwill: 0.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Goodwill: 0.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 61039000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Gross PPE: 54083000.00
PHARM.AS income_statement (annual, 2024-12-31) — Gross Profit: 261801000.00
PHARM.AS income_statement (annual, 2024-12-31) — Impairment Of Capital Assets: 5027000.00
PHARM.AS income_statement (annual, 2024-12-31) — Interest Expense: 8737000.00
PHARM.AS income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 8737000.00
PHARM.AS income_statement (annual, 2024-12-31) — Interest Income: 4858000.00
PHARM.AS income_statement (quarterly, 2024-12-31) — Interest Income: 1098000.00
PHARM.AS income_statement (annual, 2024-12-31) — Interest Income Non Operating: 4858000.00
PHARM.AS income_statement (quarterly, 2024-12-31) — Interest Income Non Operating: 1098000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Interest Paid Cff: -5598000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Interest Received Cfo: 5201000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Inventory: 55724000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Invested Capital: 303460000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Investing Cash Flow: 31618000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Investmentin Financial Assets: 3767000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Investments And Advances: 4233000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Investmentsin Associatesat Cost: 466000.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Investmentsin Associatesat Cost: 466000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Issuance Of Debt: 104539000.00
PHARM.AS cash_flow (quarterly, 2024-12-31) — Issuance Of Debt: 0.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Leases: 5432000.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Leases: 5432000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 26968000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Long Term Debt: 78154000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 105122000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Long Term Debt Issuance: 104539000.00
PHARM.AS cash_flow (quarterly, 2024-12-31) — Long Term Debt Issuance: 0.00
PHARM.AS cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -138932000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Long Term Equity Investment: 466000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 18588000.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Machinery Furniture Equipment: 18588000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Minority Interest: 0.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Minority Interest: 0.00
PHARM.AS income_statement (annual, 2024-12-31) — Minority Interests: 0.00
PHARM.AS cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: 0.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Net Debt: 27455000.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Net Debt: 27455000.00
PHARM.AS income_statement (annual, 2024-12-31) — Net Income: -11841000.00
PHARM.AS income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -11841000.00
PHARM.AS income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -11841000.00
PHARM.AS income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -11841000.00
PHARM.AS income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -11841000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -8492000.00
PHARM.AS income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -11841000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Net Intangibles Purchase And Sale: -6000.00
PHARM.AS income_statement (annual, 2024-12-31) — Net Interest Income: -5086000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: 32414000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -34393000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -34393000.00
PHARM.AS income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: -5086000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Net PPE: 24134000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 160022000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Non Current Deferred Assets: 30544000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Assets: 30544000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Non Current Prepaid Assets: 90000.00
PHARM.AS income_statement (annual, 2024-12-31) — Normalized EBITDA: 14367000.00
PHARM.AS income_statement (annual, 2024-12-31) — Normalized Income: -13286416.00
PHARM.AS cash_flow (annual, 2024-12-31) — Operating Cash Flow: -1795000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Operating Gains Losses: 1780000.00
PHARM.AS income_statement (annual, 2024-12-31) — Operating Income: -3665000.00
PHARM.AS income_statement (annual, 2024-12-31) — Operating Revenue: 297200000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 680308735.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Other Current Borrowings: 4245000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: -209000.00
PHARM.AS income_statement (annual, 2024-12-31) — Other Gand A: 17764000.00
PHARM.AS income_statement (annual, 2024-12-31) — Other Income Expense: 259000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 61039000.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Other Intangible Assets: 61039000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Other Non Cash Items: -1946000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Other Non Current Assets: 1505000.00
PHARM.AS income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: 71000.00
PHARM.AS income_statement (annual, 2024-12-31) — Other Operating Expenses: 73742000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Other Properties: 5384000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Other Receivables: 1596000.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Other Receivables: 1596000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Other Short Term Investments: 112949000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Payables: 13387000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 66611000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Prepaid Assets: 4651000.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Prepaid Assets: 4651000.00
PHARM.AS income_statement (annual, 2024-12-31) — Pretax Income: -8492000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: 5579000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Properties: 0.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Properties: 0.00
PHARM.AS cash_flow (annual, 2024-12-31) — Purchase Of Business: 0.00
PHARM.AS cash_flow (annual, 2024-12-31) — Purchase Of Intangibles: -6000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Purchase Of Investment: -284314000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Raw Materials: 425000.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Raw Materials: 425000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Receivables: 50172000.00
PHARM.AS income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 28690000.00
PHARM.AS income_statement (annual, 2024-12-31) — Reconciled Depreciation: 16070000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Repayment Of Debt: -138932000.00
PHARM.AS income_statement (annual, 2024-12-31) — Research And Development: 83147000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Restricted Cash: 0.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Restricted Cash: 0.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Retained Earnings: -275489000.00
PHARM.AS income_statement (annual, 2024-12-31) — Salaries And Wages: 74317000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Sale Of Business: 0.00
PHARM.AS cash_flow (annual, 2024-12-31) — Sale Of Investment: 316728000.00
PHARM.AS income_statement (annual, 2024-12-31) — Selling And Marketing Expense: 7135000.00
PHARM.AS income_statement (annual, 2024-12-31) — Selling General And Administration: 99216000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Share Issued: 680308735.00
PHARM.AS income_statement (annual, 2024-12-31) — Special Income Charges: -5027000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Stock Based Compensation: 11248000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Stockholders Equity: 221061000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Tangible Book Value: 160022000.00
PHARM.AS income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: 502584.00
PHARM.AS income_statement (annual, 2024-12-31) — Tax Provision: 3349000.00
PHARM.AS income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.26
PHARM.AS balance_sheet (annual, 2024-12-31) — Taxes Receivable: 7045000.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Taxes Receivable: 7045000.00
PHARM.AS cash_flow (annual, 2024-12-31) — Taxes Refund Paid: -15584000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Total Assets: 399985000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Total Capitalization: 299215000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Total Debt: 112313000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 221061000.00
PHARM.AS income_statement (annual, 2024-12-31) — Total Expenses: 300865000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 178924000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 121545000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 105122000.00
PHARM.AS income_statement (annual, 2024-12-31) — Total Operating Income As Reported: -8621000.00
PHARM.AS income_statement (annual, 2024-12-31) — Total Other Finance Cost: 1207000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Total Tax Payable: 3284000.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Total Tax Payable: 3284000.00
PHARM.AS income_statement (annual, 2024-12-31) — Total Unusual Items: 1948000.00
PHARM.AS income_statement (quarterly, 2024-12-31) — Total Unusual Items: -3211000.00
PHARM.AS income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: 1948000.00
PHARM.AS income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: -3211000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Work In Process: 39002000.00
PHARM.AS balance_sheet (quarterly, 2024-12-31) — Work In Process: 39002000.00
PHARM.AS balance_sheet (annual, 2024-12-31) — Working Capital: 204638000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — +Operating Expense: 78198000.00
PHARM.AS income_statement (quarterly, 2025-03-31) — +Total Revenue: 79094000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 68748000.00
PHARM.AS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 47487000.00